Reliant Will Add Antara, Omacor To Cardiovascular Product Line In 2005
Executive Summary
Reliant will launch two recently-approved cardiovascular products, Antara and Omacor, in 2005
You may also be interested in...
GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant
GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR
GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant
GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR
Reliant Omacor Launch Funded Through IPO; Launch Set For Late 2005
Reliant Pharmaceuticals will raise cash through an initial public offering to pay for a sales force expansion for the launch of the triglyercide therapy Omacor